Metabolic & Weight Management

Retatrutide

Retatrutide (LY3437943) — GIP/GLP-1/Glucagon Triple Agonist

A novel triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, demonstrating unprecedented weight loss of up to 24% body weight in Phase II trials — the highest reported for any pharmacological agent to date.

Weight LossTriple AgonistGLP-1Obesity

Quick Reference

Category
Metabolic & Weight Management
Research Claims
3 reviewed
Explore Research

Mechanism of Action

Retatrutide activates three complementary pathways: GLP-1R (appetite suppression, insulin secretion), GIPR (enhanced insulin response, fat metabolism), and glucagon receptor (increased energy expenditure, hepatic fat reduction). The glucagon component adds thermogenic and lipolytic effects not present in dual GIP/GLP-1 agonists.

Health Claims & Evidence

Produces up to 24% body weight reduction

StrongPhase II trial (NEJM 2023) shows 24.2% weight loss at highest dose over 48 weeks

Reduces hepatic steatosis and liver fat

Strongglucagon receptor agonism drives hepatic fat oxidation; Phase II data confirms

Improves glycemic control in type 2 diabetes

StrongPhase II data shows significant HbA1c reduction

Short-Term Effects

Significant appetite reduction and early weight loss within 4–8 weeks.

Long-Term Effects

Progressive weight loss up to 24% over 48 weeks in Phase II trials.

Side Effects

Nausea, vomiting, diarrhea, constipation, decreased appetite. Similar GI profile to other GLP-1 agonists.

Contraindications

Personal or family history of medullary thyroid carcinoma, MEN2. Not yet approved for clinical use.

This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.

Research Papers

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

Jastreboff et al. · New England Journal of Medicine · 2023

Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.

Related Peptides

Explore the research further

Our AI Research Advisor can help you explore the evidence on Retatrutide and related peptides, and prepare an educational research summary.

Explore Research